Car-T Therapy's Impact on the Patient Pathway
On Demand2020 PDC Summit Webinar Series
Car-T Therapy's Impact on the Patient Pathway
June 25, 12 p.m. – 1 p.m. CT
Speakers:
Michael Roughan, AIA, ACHA, Vice President, Health Principal, HDR
Kathleen Woods, MSN RN EDAC, Senior Healthcare Consultant, HDR
Sherman Moore, VP, Strategy, City of Hope Cancer Center
Garth Highland, Data Scientist, HDR
While we are all aware of the potential that precision medicine promises, can we effectively design facilities to accommodate these novel therapies? This session will present HDR's research on this topic. We will review how the question our City of Hope client asked about Car-T cell therapy impact on inpatient volume turned into a six-month-long research study. During this session you will be provided with case studies from prominent cancer institutions on their facility responses. Also, HDR will demonstrate our analytical tools that quantify the impact that Cytokine Release Syndrome has on immunotherapy readmission and how this impacts the metrics for inpatient bed need.
Learning Objectives:
- Produce an informed response to a difficult programming question
- Evaluate built facilities' responses to novel therapies
- Assess how parametric modeling can assist in analyzing inpatient metrics
- View how future patient pathways impact facility design
This webinar is worth 1 CEC and 1 AIA LU|HSW
Cost:
ASHE Members/PDC Registrants: $40
Non-members: $60
ASHE is an approved AIA Continuing Education Provider. If you’d like us to report your attendance to this webinar to AIA, please have your 8 digit AIA membership number ready for input at the end of the webinar. We cannot submit to AIA without this number.
e-Learning
In-Person & Live Online
Host a Program
Webinars
Lunch & Learn